Get the Stockscreener App
2.14
1.42%
0.03
After Hours:
2.05
-0.09
-4.21%
Icecure Medical Ltd stock is traded at $2.14, with a volume of 273.28K.
It is up +1.42% in the last 24 hours and down -34.76% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$2.11
Open:
$2.08
24h Volume:
273.28K
Relative Volume:
0.09
Market Cap:
$7.33M
Revenue:
$3.57M
Net Income/Loss:
$-15.74M
P/E Ratio:
-0.308
EPS:
-6.9481
Net Cash Flow:
$-15.77M
1W Performance:
-2.73%
1M Performance:
-34.76%
6M Performance:
-88.39%
1Y Performance:
-92.87%
1-Day Range:
$2.06
$2.20
1-Week Range:
$2.06
$2.25
52-Week Range:
$2.06
$42.00
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
2.14 | 7.23M | 3.57M | -15.74M | -15.77M | -6.9481 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Icecure Medical Ltd Stock (ICCM) Latest News
ICCM Looks 89.8% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Icecure Medical Receives Regulatory Approval to Market Prosense in China - marketscreener.com
IceCure Medical (ICCM) secures China nod for tumor-freezing cancer tool - Stock Titan
China approves a tumor-freezing system from IceCure - Stock Titan
IceCure Medical Ltd. (ICCM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Icecure Medical Earnings Call Signals Early Growth Phase - TipRanks
IceCure and Scovas agree for ProSense distribution in Netherlands - Yahoo Finance
IceCure (ICCM) Results at a Glance: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.58% Down in Latest TradingTax Rate Impact - vinanet.vn
Icecure Medical Ltd. Signs Exclusive Distribution Agreement with Scovas Medical for Prosense Cryoablation Systems in the Netherlands - marketscreener.com
94% success breast cancer trial backs IceCure (ICCM) in new Dutch distribution push - Stock Titan
IceCure Medical (ICCM): Commercial Adoption Is Improving, but the Reimbursement and Scale Story Still Needs More Proof - AlphaStreet
ICCM Looks 87.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
IceCure says West Cancer Center IRB clears ChoICE breast cancer cryoablation study - Bitget
IceCure's ProSense Is First and Only for Low-Risk Breast Cancer With FDA Marketing Authorization - Stock Titan
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: R - GuruFocus
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript - AOL.ca
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - vinanet.vn
IceCure Medical Ltd. SEC Filing (Aug 19, 2026) - Stock Titan
IceCure Medical (ICCM) grants 131K RSUs to North America VP - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (NASDAQ: ICCM) director lists no shares - Stock Titan
IceCure (NASDAQ: ICCM) VP now holds 106K shares and RSUs - Stock Titan
IceCure Medical (ICCM) awards COO 141K new RSUs - Stock Titan
IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake - Stock Titan
IceCure Medical (ICCM) director Chan Vincent leaves board - Stock Titan
ICCM Looks 85.8% Undervalued on GF Value™ - GuruFocus
IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0 - Stock Titan
IceCure Medical director David Salton files initial beneficial ownership statement - Bitget
IceCure Medical (ICCM) expands 2024 employee share incentive reserve - Stock Titan
Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control - Stock Titan
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
IceCure Medical (ICCM) Earnings Call zum 2. Quartal 2026: Umsatz im 1. Halbjahr steigt um 45 % - TradingKey
IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds - Stock Titan
New studies highlight FDA-approved ProSense cry... - pluang.com
Two papers examine tumor freezing beyond the primary breast tumor - Stock Titan
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation - PR Newswire
IceCure Medical regains Nasdaq bid price compliance - scanx.trade
IceCure Medical Q2 2026 Earnings Call Transcript - MarketBeat
IceCure sees Brazil adoption rise after FDA clearance - scanx.trade
IceCure Medical Ltd Q2 2026 Earnings Call Summary - Yahoo Finance
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year - GuruFocus
Earnings call transcript: IceCure Medical misses Q2 2026 estimates as shares fall - Investing.com
Icecure Medical Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
IceCure net loss widens to USD 8.78 million in H1 FY26; revenue rises 45% to USD 1.82 million - Bitget
IceCure Medical (Nasdaq: ICCM) lifts H1 revenue 45% but burns cash - Stock Titan
IceCure First-Half 2026 Earnings: 45% Revenue Growth Comes With Wider Losses - TradingKey
IceCure's Active U.S. Install Base Grows About 70%; Cash $12M - Stock Titan
Icecure Medical Q2 Results: EPS beats estimate, sales miss - scanx.trade
IceCure Medical (ICCM) names David Salton to board as independent director - Stock Titan
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 (PR Newswire) - Aktiellt
Earnings To Watch: Icecure Medical Ltd (ICCM) Q2 2026 -- GF Value Sees 452% Upside - GuruFocus
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.29%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):